Your browser doesn't support javascript.
Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients.
Haidar, Ghady; Jacobs, Jana L; Hughes Kramer, Kailey; Naqvi, Asma; Heaps, Amy; Parikh, Urvi; McCormick, Kevin D; Sobolewski, Michele D; Agha, Mounzer; Bogdanovich, Tatiana; Bushunow, Vasilii; Farah, Rafic; Hensley, Matthew; Hsu, Yen-Michael S; Johnson, Bruce; Klamar-Blain, Cynthia; Kozar, Jennifer; Lendermon, Elizabeth; Macatangay, Bernard Jc; Marino, Christopher C; Raptis, Anastasios; Salese, Erin; Silveira, Fernanda P; Leen, Ann M; Marshall, William L; Miller, Michael; Patel, Badrish; Atillasoy, Ercem; Mellors, John W.
  • Haidar G; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Jacobs JL; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Hughes Kramer K; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Naqvi A; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Heaps A; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Parikh U; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • McCormick KD; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Sobolewski MD; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Agha M; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Bogdanovich T; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Bushunow V; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Farah R; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Hensley M; Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UPMC Pittsburgh, PA, USA.
  • Hsu YS; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Johnson B; Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UPMC Pittsburgh, PA, USA.
  • Klamar-Blain C; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Kozar J; Investigational Drug Services, Department of Pharmacy, UPMC, Pittsburgh, PA, USA.
  • Lendermon E; Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, UPMC Pittsburgh, PA, USA.
  • Macatangay BJ; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Marino CC; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Raptis A; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
  • Salese E; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Silveira FP; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Leen AM; Baylor College of Medicine, Houston, TX, USA.
  • Marshall WL; CinCor, Inc, Waltham, MA, USA.
  • Miller M; AlloVir, Inc, Waltham, MA, USA.
  • Patel B; AlloVir, Inc, Waltham, MA, USA.
  • Atillasoy E; AlloVir, Inc, Waltham, MA, USA.
  • Mellors JW; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Clin Infect Dis ; 2023 Apr 20.
Article in English | MEDLINE | ID: covidwho-20236445
ABSTRACT
We administered SARS-CoV-2 VST under emergency IND to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VST in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to two courses of remdesivir and experienced sustained recovery after VST. The use VST in immunocompromised patient with persistent COVID-19 requires further study.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Long Covid Language: English Journal subject: Communicable Diseases Year: 2023 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Long Covid Language: English Journal subject: Communicable Diseases Year: 2023 Document Type: Article Affiliation country: Cid